Pathology News
editor

About Editor

This author has not yet filled in any details.
So far Editor has created 933 blog entries.

February 2026

AimedBio Announces Strategic Investment and Joint Research with AIVIS in AI-Based Biomarker Quantification

2026-03-02T13:42:58+00:00

AimedBio announced on February 3 that it has entered into a joint research agreement with AIVIS, an AI-based digital pathology company, and completed a strategic equity investment (SI) to strengthen its antibody–drug conjugate (ADC) drug development capabilities. The size of the investment was not disclosed. Founded in January 2021, AIVIS provides AI-powered solutions that quantitatively analyze [...]

AimedBio Announces Strategic Investment and Joint Research with AIVIS in AI-Based Biomarker Quantification2026-03-02T13:42:58+00:00

KLAS Recognition as a Catalyst for What Comes Next

2026-03-01T17:20:34+00:00

We are proud to mark a significant milestone: HALO AP® earned 94.9/100* for overall customer rating in the 2026 Best in KLAS Awards – Global Software report for digital pathology. Because KLAS distinction is driven entirely by direct customer feedback, this recognition reflects the real-world performance, reliability, and impact of our platform in daily pathology practice. Although an eligibility [...]

KLAS Recognition as a Catalyst for What Comes Next2026-03-01T17:20:34+00:00

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

2026-02-26T09:41:34+00:00

 40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers Illumina, Inc. today unveiled an 18-month roadmap of innovations that enhance the power and value of [...]

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility2026-02-26T09:41:34+00:00

AI’s GROWING ROLE IN THE FUTURE OF PATHOLOGY W/ Adam Cole and Jason Camilletti

2026-02-26T16:21:00+00:00

In this episode, I interview Adam Cole, MD and Jason Camilletti, two innovators who are pioneering the future of digital pathology. Adam, an anatomic pathologist and CEO of TruCore Pathology, and Jason, CEO of PathNet Labs, bring unique perspectives from their military backgrounds to their leadership in transforming pathology using digital tools and artificial intelligence (AI). We delve into how AI is reshaping [...]

AI’s GROWING ROLE IN THE FUTURE OF PATHOLOGY W/ Adam Cole and Jason Camilletti2026-02-26T16:21:00+00:00

Lumea’s IMS Viewer+™ Achieves CE Marking Under IVDR, Expanding Clinical Use Across Europe

2026-02-25T13:50:22+00:00

Lumea’s Viewer+™ software is now CE marked under IVDR for clinical use across Europe, making Lumea the most versatile browser-based diagnostic hub for the global market. Precision in medicine is a necessity. Pathology data informs nearly 70% of medical decisions, yet diagnostic quality is often hindered (or compromised) by a combination of inconsistencies in tissue handling and siloed [...]

Lumea’s IMS Viewer+™ Achieves CE Marking Under IVDR, Expanding Clinical Use Across Europe2026-02-25T13:50:22+00:00

Pathology Education: The Digital Future Is Here

2026-02-25T10:53:42+00:00

The next generations of pathologists are demanding digital education now As medicine becomes more precise and data-driven, pathology is undergoing a transformative shift toward digital technology. This transition promises to revolutionize how pathologists work, improving accuracy, efficiency, and collaboration, while ultimately enhancing patient outcomes. Nowhere is this transformation happening faster or more profoundly than in [...]

Pathology Education: The Digital Future Is Here2026-02-25T10:53:42+00:00

Lumito and Atlas Antibodies Enter Strategic Partnership to Advance High-resolution Tissue Imaging

2026-02-25T10:11:11+00:00

Lumito and Atlas Antibodies AB (“Atlas Antibodies”) today announce a strategic partnership aimed at accelerating innovation in tissue analysis and strengthening their respective positions in a growing global market. By combining Lumito’s proprietary high-sensitivity imaging technology with Atlas Antibodies’ extensively validated antibody portfolio, the collaboration is designed to create differentiated, value-driven solutions for research, translational applications, [...]

Lumito and Atlas Antibodies Enter Strategic Partnership to Advance High-resolution Tissue Imaging2026-02-25T10:11:11+00:00

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

2026-02-25T10:05:40+00:00

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care Labcorp, a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its [...]

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide2026-02-25T10:05:40+00:00

AI-Powered Proteogenomics Identifies Mitochondrial Signatures as Predictors of Melanoma Recurrence and Therapy Response

2026-02-23T10:00:25+00:00

by Christos Evangelou, MSc, PhD – Medical Writer and Editor  The Melanoma MEGA-Study, a decade-long study encompassing 1,653 patients from Hungary, integrated proteogenomics, AI-driven digital pathology, and clinical data to improve risk stratification for patients with melanoma. In an interview with Pathology News, Jeovanis Gil, PhD, one of the lead investigators of the Melanoma MEGA-Study, [...]

AI-Powered Proteogenomics Identifies Mitochondrial Signatures as Predictors of Melanoma Recurrence and Therapy Response2026-02-23T10:00:25+00:00

Taking AIM at Histologic Scoring Variability in Ulcerative Colitis

2026-02-24T13:28:54+00:00

Inflammatory bowel diseases, including ulcerative colitis (UC), are chronic gastrointestinal conditions that profoundly impact patients’ quality of life. Recently, treatment goals for patients with UC have shifted away from symptom control towards true healing of the colonic epithelium, with histologic remission emerging as a key metric of disease activity.1 Factors pathologists consider when examining UC biopsies [...]

Taking AIM at Histologic Scoring Variability in Ulcerative Colitis2026-02-24T13:28:54+00:00
Legal

Bioincyte Ltd is registered in the United Kingdom
under company number 13037659

Get in touch

© Copyright 2025, Bioincyte Ltd

Fields marked with an asterisk (*) are required.
By submitting you agree to our T&C and Privacy Policy

Go to Top